Repligen Corporation ($RGEN) Stock Forecast: Up 5.0% Today

What is Repligen Corporation?

Repligen Corporation (RGEN) is a biotechnology company specializing in bioproduction consumables essential for the development and manufacturing of biopharmaceuticals. The company has been experiencing a bullish market movement.

Why is Repligen Corporation going up?

RGEN stock is up 5.0% on Mar 17, 2026 16:55

• Institutional confidence in Repligen Corporation surged as Iron Triangle Partners LP, Holocene Advisors LP, and Geneva Capital Management significantly increased their stakes in the company, reflecting strong growth prospects.
• Repligen reported stronger-than-expected Q3 earnings and revenue, surpassing quarterly estimates and providing optimistic FY2026 guidance, contributing to the bullish market movement.
• The projected boom in the Biological Product IgG Purification Medium Market, where Repligen is a key player, further fueled investor optimism and interest in the company's growth potential.
• Analysts maintaining a "Moderate Buy" consensus rating with a target price of $174.58 for Repligen amidst positive earnings reports and strategic investments also supported the bullish trend in the stock.

RGEN Price Chart

RGEN Technical Analysis

RGEN News

270,000 Shares in Repligen Corporation $RGEN Acquired by Iron Triangle Partners LP

Iron Triangle Partners LP significantly increased its stake in Repligen Corporation (NASDAQ:RGEN) during Q3 2025, acquiring 270,000 shares valued at approximately $36.09 million. This move, along with substantial investments from other institutional firms, pushed institutional ownership to nearly 97.64%, reflecting robust institutional confidence. Despite recent price target adjustments by analysts, Repligen maintains a "Moderate Buy" consensus rating and recently surpassed quarterly earnings estimates.

https://www.marketbeat.com/instant-alerts/filing-270000-shares-in-repligen-corporation-rgen-acquired-by-iron-triangle-partners-lp-2026-03-16/

Holocene Advisors LP Boosts Stock Position in Repligen Corporation $RGEN

Holocene Advisors LP significantly increased its stake in Repligen Corporation (NASDAQ:RGEN) by 47.0% in Q3, now owning 1,377,104 shares valued at approximately $184.1 million. Other institutional investors also adjusted their positions. Repligen reported stronger-than-expected Q3 earnings and revenue, providing FY2026 guidance, while analysts maintain a "Moderate Buy" rating with a consensus target price of $174.58.

https://www.marketbeat.com/instant-alerts/filing-holocene-advisors-lp-boosts-stock-position-in-repligen-corporation-rgen-2026-03-16/

Repligen Shares Purchased by Geneva Capital Management

Geneva Capital Management LLC has significantly increased its stake in Repligen Corporation (NASDAQ:RGEN) by 22.4% in the third quarter of 2026, boosting its holdings to approximately 596,768 shares. This makes Geneva Capital one of Repligen's largest shareholders, signaling strong confidence in the biotechnology company's growth prospects. Repligen is a key supplier of bioproduction consumables, crucial for the development and manufacturing of biopharmaceuticals.

https://nationaltoday.com/us/ma/waltham/news/2026/03/11/repligen-shares-purchased-by-geneva-capital-management/

Biological Product IgG Purification Medium Market Is Going to Boom | Repligen Corporation • Agilent Technologies

The Biological Product IgG Purification Medium Market is projected to see substantial growth from 2026 to 2033, driven by increasing demand and innovation. A new report by Coherent Market Insights provides a deep dive into market trends, competitive landscapes, and growth opportunities, offering essential insights for industry leaders. Key players include Thermo Fisher Scientific, Merck KGaA, and Repligen Corporation.

https://www.openpr.com/news/4421743/biological-product-igg-purification-medium-market-is-going

Repligen Corporation $RGEN Shares Purchased by Geneva Capital Management LLC

Geneva Capital Management LLC significantly increased its stake in Repligen Corporation (RGEN) by 22.4% in Q3, now holding 596,768 shares valued at approximately $79.8 million. The biotechnology company recently exceeded earnings expectations, reporting Q3 EPS of $0.49 and revenue of $197.9 million, while analysts have a "Moderate Buy" consensus rating with a target price of $174.58.

https://www.marketbeat.com/instant-alerts/filing-repligen-corporation-rgen-shares-purchased-by-geneva-capital-management-llc-2026-03-11/

Trending Today

Ethereum ($ETH) Crypto Forecast: Up 5.0% Today

Silver ($XAG) Commodity Forecast: Up 6.1% Today

Sky ($SKY) Crypto Forecast: Up 5.2% Today

Natural Gas ($GAS) Commodity Forecast: Down 5.1% Today

Heating Oil ($HEATOIL) Commodity Forecast: Down 7.9% Today

Gasoline ($GASOLINE) Commodity Forecast: Down 6.9% Today

Brent Crude Oil ($BRENT) Commodity Forecast: Down 7.9% Today

Crude Oil ($CRUDE) Commodity Forecast: Down 7.2% Today

Bitcoin ($BTC) Crypto Forecast: Up 5.1% Today

Simon Property Group Inc. ($SPG) Stock Forecast: Down 1.5% Today

Repligen Corporation Price History

14.00.2026 - RGEN Stock was down 5.1%

• AI models analyzing RGEN suggest choppy conditions and conflicting sentiment across various time horizons.
• Institutional trading strategies suggest positions, momentum breakouts, and risk hedging with specified entry, target, and stop-loss levels.
• Multi-timeframe signal strengths, support, and resistance levels paint a challenging outlook for RGEN in the near-term, mid-term, and long-term.
• The bearish movement in RGEN's stock price is possibly due to the choppy market conditions and conflicting sentiment identified in the AI analysis, which have led to heightened selling pressure and a downward trend in the stock.

11.02.2026 - RGEN Stock was down 5.2%

• The bearish movement in RGEN's stock today could be attributed to concerns regarding declining operating margins and reduced return on invested capital, despite the company's improved earnings report.
• The participation of Repligen Corporation in upcoming investor conferences may have failed to reassure investors about the company's growth potential, leading to a negative sentiment in the market.
• Investors might be cautious about the company's ability to address challenges like scale disadvantages and margin pressure, which could be contributing to the bearish trend in RGEN's stock price today.

12.01.2026 - RGEN Stock was down 5.1%

• The announcement of Repligen Corporation reporting its fourth quarter and full year 2025 financial results may have raised concerns among investors, leading to a bearish sentiment.
• Azzad Asset Management Inc. ADV reducing its stake in RGEN by 60.7% in Q3 and the significant insider selling of shares in the last three months could have contributed to the negative market movement.
• Despite the endorsement from Baron Health Care Fund for Repligen's AI-driven bioprocessing platform, market sentiment may have been influenced by the cautionary advice for investors to consider various perspectives and risks, potentially impacting the stock price negatively.

25.01.2026 - RGEN Stock was down 3.9%

• Despite Repligen's impressive Q4 2025 earnings beat and revenue growth, the stock experienced a significant bearish movement.
• The bearish trend can be attributed to the market's reaction to the company's 2026 guidance, which fell below analyst consensus, indicating a cautious outlook from management.
• Investors may have reacted negatively to the discrepancy between the strong quarterly performance and the lower-than-expected revenue forecast for the upcoming year, leading to the bearish movement in RGEN stock.
• The overall positive sentiment towards Repligen's growth momentum and strategic innovations, as well as the favorable analyst ratings, suggests that the bearish market movement today may present a potential buying opportunity for long-term investors eyeing the company's growth prospects.

24.01.2026 - RGEN Stock was up 1.1%

• Repligen (RGEN) saw significant positive movement in the market, likely influenced by favorable investor sentiment and expectations for the upcoming earnings release.
• Analysts forecast substantial year-over-year revenue growth for Repligen, suggesting a promising financial outlook.
• The recent acquisition of a stake by CenterBook Partners LP and increased activity from other institutional investors may have bolstered the optimistic market sentiment, indicating confidence in Repligen's future.
• Emphasis on the recovery of the bioprocessing industry, ongoing revenue growth, and margin expansion through new product offerings likely contributed to the positive market sentiment towards the company.

03.02.2026 - RGEN Stock was down 5.3%

• Repligen (RGEN) witnessed a 3.09% decline in shares attributed to a cautious outlook for 2026, despite posting robust Q4 2025 results, eliciting varied responses from investors.
• Analysts suggest that the stock may be overvalued based on its Price/Sales ratio compared to industry norms and the "Fair Ratio" according to Simply Wall St, potentially contributing to the downward trend.
• A reduction in Repligen's price target by Evercore ISI Group to $170 from $180 could have further dampened investor sentiment, although other analysts anticipate significant upside potential.
• Market behavior likely reflects investor worries about the company's revenue forecast, risks associated with biotech funding fluctuations, and concerns regarding customer concentration as mentioned in the provided guidance.

05.01.2026 - RGEN Stock was down 6.1%

• The bearish movement in RGEN's stock price could be attributed to significant insider selling activity by company executives and institutional investors reducing their holdings.
• Despite the positive long-term outlook, the near and mid-term sentiment appears weak, leading to a downside target of 13.3%.
• The mixed institutional investor activity, with some increasing and others decreasing their positions, might have added to the selling pressure on RGEN's stock.
• The overall market sentiment towards RGEN remains cautiously optimistic, as indicated by the "Moderate Buy" consensus rating from Wall Street analysts with an average price target of $179.62.

11.01.2026 - RGEN Stock was down 5.0%

• The anticipation of Repligen's fourth quarter and full year 2025 financial results might have caused uncertainty among investors, contributing to the bearish sentiment.
• Azzad Asset Management Inc. significantly reduced its stake in RGEN by 60.7%, possibly adding to the selling pressure and indicating reduced confidence from institutional investors.
• Baron Health Care Fund endorsed Repligen's AI-driven bioprocessing platform, but the market seemed more focused on recent insider selling and overall weak sentiment highlighted in technical analysis.
• An analysis reflecting a negative near and mid-term sentiment, suggesting a short setup and downside target, likely influenced traders to adopt a bearish position on RGEN. Monitoring price action is crucial for making tactical trading decisions.

21.10.2025 - RGEN Stock was up 5.5%

• The rise in RGEN's stock price is possibly a result of favorable investor sentiment towards the company's P/E ratio.
• Despite a slight decline in the previous month, the substantial increase in the stock price over the last year indicates promising long-term growth prospects, which may have attracted investors.
• The 0.65% increase in the current market session could also be influenced by general market positivity or specific industry trends benefiting biopharmaceutical firms like Repligen Inc.

04.02.2026 - RGEN Stock was up 6.1%

• Repligen's COO and CEO both had tax-withholding share dispositions, which could indicate a routine financial activity rather than a significant event impacting the company's fundamentals.
• Despite a recent drop in share price on February 27, analysts remain optimistic about Repligen, with a forecasted upside potential of around 45-47%.
• The mixed investor reactions to Repligen's strong Q4 2025 results and cautious 2026 guidance suggest uncertainty about the company's future performance, particularly regarding revenue and EPS projections.
• The recommendation to avoid investing in Repligen due to concerns about distribution channels, operating margins, and return on invested capital may have contributed to the bearish movement on February 27, but the overall bullish trend today could be attributed to the positive long-term outlook and potential growth opportunities in the bioprocessing industry.

17.02.2026 - RGEN Stock was up 5.0%

• Institutional confidence in Repligen Corporation surged as Iron Triangle Partners LP, Holocene Advisors LP, and Geneva Capital Management significantly increased their stakes in the company, reflecting strong growth prospects.
• Repligen reported stronger-than-expected Q3 earnings and revenue, surpassing quarterly estimates and providing optimistic FY2026 guidance, contributing to the bullish market movement.
• The projected boom in the Biological Product IgG Purification Medium Market, where Repligen is a key player, further fueled investor optimism and interest in the company's growth potential.
• Analysts maintaining a "Moderate Buy" consensus rating with a target price of $174.58 for Repligen amidst positive earnings reports and strategic investments also supported the bullish trend in the stock.

12.02.2026 - RGEN Stock was down 5.2%

• The bearish movement in RGEN's stock today could be attributed to concerns about potential valuation risks due to its high P/E ratio of 138x, significantly above the industry average.
• Despite the positive financial performance and exceeding earnings expectations, the pressure faced by healthcare stocks after a weak February jobs report might have contributed to the downward movement in RGEN's stock price.
• The increased stake by institutional investors like Geneva Capital Management LLC and Schroder Investment Management Group could indicate a vote of confidence in the company's long-term prospects, potentially mitigating some of the short-term bearish sentiment.
• Investors may be reevaluating RGEN's valuation and growth prospects in light of mixed sentiment and the need to carefully analyze the company's financial numbers amidst market uncertainties.